ArriVent BioPharma, Inc. (AVBP) Stock Statistics & Valuation Metrics

ArriVent BioPharma, Inc. has a market cap or net worth of $1.57B. The enterprise value is $1.40B.

ArriVent BioPharma, Inc. has 46,574,930 shares outstanding. The number of shares has decreased by -2.65% in one year.

ArriVent BioPharma, Inc.’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -57.78%.

The current PE Ratio of ArriVent BioPharma, Inc. is ―. ArriVent BioPharma, Inc.’s PEG ratio is -0.07.

In the last 12 months, ArriVent BioPharma, Inc. had revenue of 0.00 and earned -166.31M in profits. Earnings per share was -4.32.

In the last 12 months, operating cash flow was -134.47M and capital expenditures 0.00, giving a free cash flow of -134.47M billion.

ArriVent BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

ArriVent BioPharma, Inc. upcoming earnings date is Aug 18, 2026, After Close (Confirmed).

ArriVent BioPharma, Inc. as a current ratio of 12.83, with Debt / Equity ratio of 0.13%

In the past 12 months, ArriVent BioPharma, Inc. has paid 0.00 in taxes.

ArriVent BioPharma, Inc. EV to EBITDA ratio is -4.38, with an EV/FCF ratio of -4.54.

ArriVent BioPharma, Inc. has $326.38M in cash and marketable securities with $419.00K in debt, giving a net cash position of $325.96M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for ArriVent BioPharma, Inc. is $43.08, which is 11.43% higher than the current price. The consensus rating is Strong Buy